C.K. Olsen

620 total citations · 1 hit paper
12 papers, 446 citations indexed

About

C.K. Olsen is a scholar working on Pharmacology, Dermatology and Immunology and Allergy. According to data from OpenAlex, C.K. Olsen has authored 12 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 3 papers in Dermatology and 3 papers in Immunology and Allergy. Recurrent topics in C.K. Olsen's work include Treatment of Major Depression (6 papers), Allergic Rhinitis and Sensitization (3 papers) and Food Allergy and Anaphylaxis Research (3 papers). C.K. Olsen is often cited by papers focused on Treatment of Major Depression (6 papers), Allergic Rhinitis and Sensitization (3 papers) and Food Allergy and Anaphylaxis Research (3 papers). C.K. Olsen collaborates with scholars based in Denmark, United States and United Kingdom. C.K. Olsen's co-authors include Jonathan I. Silverberg, Andrew Alexis, Boni E. Elewski, Stephan Weidinger, Thomas Bieber, B K Bang, DirkJan Hijnen, D. Toth, Andrew Pink and Azra Kurbasic and has published in prestigious journals such as Neuropsychopharmacology, Molecular Psychiatry and Journal of Affective Disorders.

In The Last Decade

C.K. Olsen

12 papers receiving 440 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

2020 213 citations Jonathan I. Silverberg, D. Toth et al. British Journal of Dermatology profile →

Peers

C.K. Olsen

DERMA

PHYSI

RHEUM

PHARM

L. Ghys Belgium

Astrid Stumpf Germany

H.J.A. Hunter United Kingdom

Jared Sprague United States

M. Thomas Sweden

Michelle Magid United States

Rocı́o Herrera Mexico

Nicole E. Kramer United States

Goele Bosmans Belgium

Subhashie Wijemanne United States

L. Ghys Belgium

C.K. Olsen

63 ×0.2

DERMA

119 ×0.5

181 ×1.6

PHYSI

53 ×0.7

RHEUM

45 ×0.7

PHARM

Citations per year, relative to C.K. Olsen C.K. Olsen (= 1×) peers L. Ghys

Countries citing papers authored by C.K. Olsen

Since Specialization

Citations

This map shows the geographic impact of C.K. Olsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.K. Olsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.K. Olsen more than expected).

Fields of papers citing papers by C.K. Olsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.K. Olsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.K. Olsen. The network helps show where C.K. Olsen may publish in the future.

Co-authorship network of co-authors of C.K. Olsen

This figure shows the co-authorship network connecting the top 25 collaborators of C.K. Olsen. A scholar is included among the top collaborators of C.K. Olsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.K. Olsen. C.K. Olsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Simpson, Eric L., Joseph F. Merola, Jonathan I. Silverberg, et al.. (2022). Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. British Journal of Dermatology. 187(6). 888–899. 53 indexed citations

Wollenberg, Andreas, Lisa A. Beck, Marjolein de Bruin‐Weller, et al.. (2021). Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials. British Journal of Dermatology. 186(3). 453–465. 53 indexed citations

Silverberg, Jonathan I., D. Toth, Thomas Bieber, et al.. (2020). Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*. British Journal of Dermatology. 184(3). 450–463. 213 indexed citations breakdown →

Nierenberg, Andrew A., Henrik Loft, & C.K. Olsen. (2019). Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. Journal of Affective Disorders. 250. 35–42. 22 indexed citations

Smith, Jackson E. T., Michael Browning, Silke Conen, et al.. (2017). Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Molecular Psychiatry. 23(5). 1127–1133. 71 indexed citations

Conen, Silke, Shane McKie, Richard Smallman, et al.. (2015). P.2.f.014 Effects of vortioxetine on resting-state activity in subjects remitted from depression and healthy controls. European Neuropsychopharmacology. 25. S442–S442. 5 indexed citations

Jacobson, W., et al.. (2015). P.2.h.012 Effect of vortioxetine on functional capacity in patients with major depressive disorder with self-reported cognitive dysfunction. European Neuropsychopharmacology. 25. S460–S460. 1 indexed citations

Browning, Michael, John A. Smith, Silke Conen, et al.. (2015). P.1.i.026 Vortioxetine reduces BOLD signal during performance of the N-back task in subjects remitted from depression and healthy control participants. European Neuropsychopharmacology. 25. S314–S315. 2 indexed citations

Browning, Michael, John A. Smith, Silke Conen, et al.. (2014). Vortioxetine Reduces BOLD Signal during Performance of the N-Back Task in Subjects Remitted from Depression and Healthy Control Participants. Neuropsychopharmacology. 39. 2 indexed citations

10.

Keefe, Richard S.E., Atul R. Mahableshwarkar, & C.K. Olsen. (2013). P.2.f.013 Clinical evidence for improvement in cognitive dysfunction in patients with major depressive disorder (MDD) after treatment with vortioxetine. European Neuropsychopharmacology. 23. S402–S403. 2 indexed citations

11.

Katona, Cornelius, Thomas Michael Hansen, & C.K. Olsen. (2012). P.2.c.015 A randomised, double-blind, placebo-controlled, active-referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. European Neuropsychopharmacology. 22. S258–S259. 3 indexed citations

12.

Olsen, C.K., S. Hogg, & M.D.S. Lapiz. (2002). Tonic immobility in guinea pigs: A behavioural response for detecting an anxiolytic-like effect?. Behavioural Pharmacology. 13(4). 261–269. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact